IRVINE, Calif., April 14, 2009 (GLOBE NEWSWIRE) -- SenoRx Inc. (Nasdaq:SENO) today announced the introduction of StarchMark, the company's newest addition to its line of biopsy site markers. SenoRx is a market leader in breast biopsy markers, with the widest array of advanced markers offering enhanced visualization in all three imaging modalities -- stereotactic, ultrasound and MRI. StarchMark is the first and only breast biopsy marker that uses polysaccharide (starch) pellets to help manage and control bleeding. StarchMark received 510(k) clearance in August 2008.
"Starch is a known haemostatic agent with a long history of use to help control bleeding," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "This novel use in our new StarchMark biopsy site marker provides an effective option for patients with known bleeding issues."
SenoRx plans a full commercial launch of StarchMark at the 10th Annual Meeting of the American Society of Breast Surgeons in San Diego, April 22-26, 2009, where a white paper on the initial results utilizing the StarchMark entitled "A Prospective Clinical Study of the SenoRx StarchMark Biopsy Site Marker," authored by John D. Corbitt, MD and Lori Anthony, PAC, MPH, will be available.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605